The team at Clincierge is very conscious of the need to expand the diversity profile of patients included in clinical trials. We do this by first identifying the particular barriers to access that deter participants, such as emotional, physical, and financial considerations. Then we create strategies to address them head-on.
Our study suggests that we may be able to cure monogenic diseases, especially monogenic diabetes (i.e., diabetes caused by gene mutations) and monogenic retinal degeneration, using gene editing in combination with patient-derived iPSCs.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.